secwatch.observer — SEC 8-K summary
======================================

Issuer:     Milestone Pharmaceuticals Inc. (MIST)
CIK:        0001408443
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001104659-24-116493
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Milestone reports Q3 net loss of $9.4M; PDUFA for CARDAMYST set for March 27, 2025
--------------------------------------------------------------------------------

- PDUFA target date for CARDAMYST (etripamil) in PSVT is March 27, 2025.
- China Phase 3 met primary endpoint: 40.5% conversion vs 15.9% placebo within 30 min (HR=3.00, p<0.001).
- Phase 3 trial in AFib-RVR expected to start H1 2025 with repeat-dose 70 mg regimen.
- Cash, equivalents and short-term investments $76.4M at Sep 30, 2024, up from $66.0M at Dec 31, 2023.
- Net loss narrowed to $9.4M in Q3 2024 vs $15.1M in Q3 2023; R&D expense $4.0M vs $6.7M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1408443/000110465924116493/0001104659-24-116493-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1408443/000110465924116493/tm2428099d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-116493

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer